CN101053556A - 一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 - Google Patents
一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 Download PDFInfo
- Publication number
- CN101053556A CN101053556A CN 200610046307 CN200610046307A CN101053556A CN 101053556 A CN101053556 A CN 101053556A CN 200610046307 CN200610046307 CN 200610046307 CN 200610046307 A CN200610046307 A CN 200610046307A CN 101053556 A CN101053556 A CN 101053556A
- Authority
- CN
- China
- Prior art keywords
- ubiquinone
- beta
- water
- preparation
- hydroxypropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 120
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 102
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229920000858 Cyclodextrin Polymers 0.000 title claims description 46
- 238000002360 preparation method Methods 0.000 title claims description 32
- 239000001116 FEMA 4028 Substances 0.000 title claims description 27
- 229960004853 betadex Drugs 0.000 title claims description 27
- 229940110767 coenzyme Q10 Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 71
- 229940035936 ubiquinone Drugs 0.000 claims description 70
- 239000002994 raw material Substances 0.000 claims description 23
- 238000007664 blowing Methods 0.000 claims description 17
- 238000005516 engineering process Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 229940100691 oral capsule Drugs 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 claims description 2
- 229940096978 oral tablet Drugs 0.000 claims description 2
- 235000011837 pasties Nutrition 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000004090 dissolution Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 2
- 231100000283 hepatitis Toxicity 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 8
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 4
- 229950005162 benexate Drugs 0.000 description 3
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 125000001655 ubiquinone group Chemical group 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
样品 | 相对溶出度(%) | |||
5min | 15min | 60min | 120min | |
本发明辅酶Q10包合物 | 97 | 97 | 99 | 98 |
辅酶Q10 | 0 | 0 | 0 | 0 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100463070A CN101053556B (zh) | 2006-04-14 | 2006-04-14 | 一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100463070A CN101053556B (zh) | 2006-04-14 | 2006-04-14 | 一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101053556A true CN101053556A (zh) | 2007-10-17 |
CN101053556B CN101053556B (zh) | 2010-12-08 |
Family
ID=38793725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100463070A Active CN101053556B (zh) | 2006-04-14 | 2006-04-14 | 一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101053556B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485626B (zh) * | 2009-02-11 | 2011-01-19 | 神舟天辰科技实业有限公司 | 一种含有辅酶q10纳米颗粒的水溶液及其制备方法 |
CN102512425A (zh) * | 2011-11-17 | 2012-06-27 | 淮南联合大学 | 一种熊果酸环糊精包合物的制备方法 |
CN102698284A (zh) * | 2012-05-31 | 2012-10-03 | 沈阳药科大学 | 辅酶q10/直链淀粉包合物及其制备方法 |
CN103230587A (zh) * | 2013-05-10 | 2013-08-07 | 汪华东 | 一种鳄鱼血红蛋白肽的组合物及其制备方法 |
CN103272245A (zh) * | 2013-05-25 | 2013-09-04 | 江苏丰园生物技术有限公司 | 一种姜黄素与混合环糊精包合物及其制备方法 |
CN106729744A (zh) * | 2016-12-26 | 2017-05-31 | 西安医学院 | 一种辅酶Q10羟丙基‑β‑环糊精包合物的制备方法 |
CN108079314A (zh) * | 2018-02-11 | 2018-05-29 | 辽宁万嘉医药科技有限公司 | 辅酶q10与二十八烷醇环糊精多元超分子包合物及其制备方法 |
CN109157515A (zh) * | 2018-09-05 | 2019-01-08 | 辽宁万嘉医药科技有限公司 | 辅酶q10包合物自组装脂质体前体及其制备方法 |
JP2019178154A (ja) * | 2019-06-18 | 2019-10-17 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
CN111249249A (zh) * | 2020-02-14 | 2020-06-09 | 上海宇昂水性新材料科技股份有限公司 | 一种辅酶q10的海藻酸钠微球及其制备方法 |
CN111467502A (zh) * | 2019-01-24 | 2020-07-31 | 上海融澈水性材料有限公司 | 一种水溶性辅酶q10组合物及其制备方法 |
CN115120515A (zh) * | 2022-08-08 | 2022-09-30 | 山东省药学科学院 | 一种美白祛斑组合物及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108719988B (zh) * | 2018-05-31 | 2022-02-15 | 北京素维生物科技有限公司 | 一种辅酶q10包合物及其制备工艺 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1870982B (zh) * | 2003-10-31 | 2010-05-26 | 株式会社钟化 | 含还原型辅酶q的组合物 |
-
2006
- 2006-04-14 CN CN2006100463070A patent/CN101053556B/zh active Active
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485626B (zh) * | 2009-02-11 | 2011-01-19 | 神舟天辰科技实业有限公司 | 一种含有辅酶q10纳米颗粒的水溶液及其制备方法 |
CN102512425A (zh) * | 2011-11-17 | 2012-06-27 | 淮南联合大学 | 一种熊果酸环糊精包合物的制备方法 |
CN102698284A (zh) * | 2012-05-31 | 2012-10-03 | 沈阳药科大学 | 辅酶q10/直链淀粉包合物及其制备方法 |
CN102698284B (zh) * | 2012-05-31 | 2014-09-10 | 沈阳药科大学 | 辅酶q10/直链淀粉包合物及其制备方法 |
CN103230587A (zh) * | 2013-05-10 | 2013-08-07 | 汪华东 | 一种鳄鱼血红蛋白肽的组合物及其制备方法 |
CN103230587B (zh) * | 2013-05-10 | 2015-01-21 | 汪华东 | 一种鳄鱼血红蛋白肽的组合物及其制备方法 |
CN103272245A (zh) * | 2013-05-25 | 2013-09-04 | 江苏丰园生物技术有限公司 | 一种姜黄素与混合环糊精包合物及其制备方法 |
CN106729744A (zh) * | 2016-12-26 | 2017-05-31 | 西安医学院 | 一种辅酶Q10羟丙基‑β‑环糊精包合物的制备方法 |
CN108079314A (zh) * | 2018-02-11 | 2018-05-29 | 辽宁万嘉医药科技有限公司 | 辅酶q10与二十八烷醇环糊精多元超分子包合物及其制备方法 |
CN109157515A (zh) * | 2018-09-05 | 2019-01-08 | 辽宁万嘉医药科技有限公司 | 辅酶q10包合物自组装脂质体前体及其制备方法 |
CN109157515B (zh) * | 2018-09-05 | 2020-11-03 | 辽宁万嘉医药科技有限公司 | 辅酶q10包合物自组装脂质体前体及其制备方法 |
CN111467502A (zh) * | 2019-01-24 | 2020-07-31 | 上海融澈水性材料有限公司 | 一种水溶性辅酶q10组合物及其制备方法 |
JP2019178154A (ja) * | 2019-06-18 | 2019-10-17 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
JP2022167905A (ja) * | 2019-06-18 | 2022-11-04 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
CN111249249A (zh) * | 2020-02-14 | 2020-06-09 | 上海宇昂水性新材料科技股份有限公司 | 一种辅酶q10的海藻酸钠微球及其制备方法 |
CN111249249B (zh) * | 2020-02-14 | 2022-06-10 | 上海宇昂水性新材料科技股份有限公司 | 一种辅酶q10的海藻酸钠微球及其制备方法 |
CN115120515A (zh) * | 2022-08-08 | 2022-09-30 | 山东省药学科学院 | 一种美白祛斑组合物及其制备方法 |
CN115120515B (zh) * | 2022-08-08 | 2023-10-17 | 山东省药学科学院 | 一种美白祛斑组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101053556B (zh) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101053556A (zh) | 一种水溶性辅酶Q10羟丙基-β-环糊精包合物及制备方法 | |
CN1091368C (zh) | 含辅酶q10的药学组合物 | |
CN101172102B (zh) | 一种水溶性辅酶q10超分子组合物及制备方法 | |
CN1981750B (zh) | 一种水溶性辅酶q10组合物及制备方法 | |
CN105561329A (zh) | 水溶性辅酶Q10与α-硫辛酸复配的环糊精三元超分子包合物及制备方法 | |
CN1965805A (zh) | 辅酶q10亚微乳注射液及制备方法 | |
CN101028437A (zh) | 一种防治心脑血管疾病的中药有效部位组合物及制备方法 | |
CN1264502C (zh) | 一种注射用醒脑静冻干粉及其制备新方法 | |
CN1296089C (zh) | 一种莪术注射制剂及其制备方法 | |
CN1686389A (zh) | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 | |
CN1248698C (zh) | 一种治疗冠心病或冠心病合并心功能不全的药物及其制备方法 | |
CN1285332C (zh) | 一种稳定长效的银杏酮酯软胶囊及其制备方法 | |
CN1634509A (zh) | 一种治疗疼痛的伊痛舒滴丸及其制备方法 | |
CN1895346A (zh) | 一种治疗心脑血管疾病的中药制剂及制备方法 | |
CN1271995C (zh) | 一种心痛宁口腔崩解片及其制备方法 | |
CN1679669A (zh) | 远志滴丸及其制备方法 | |
CN1309379C (zh) | 细辛脑滴丸及其制备方法 | |
CN1899369A (zh) | 一种救心注射制剂及其制备方法 | |
CN1278705C (zh) | 一种通心络口腔崩解片及其制备方法 | |
CN1686385A (zh) | 复方麝香滴丸及其制备方法 | |
CN1197585C (zh) | 黄精多糖的用途 | |
CN1528298A (zh) | 异卡波肼滴丸及其制备方法 | |
CN1709420A (zh) | 益母草滴丸及其制备方法 | |
CN1698831A (zh) | 一种治疗肝炎的茵栀黄滴丸及其制备方法 | |
CN1698833A (zh) | 复方苦参滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Patentee after: Shenyang Wanjia Biotechnology Institute Co., Ltd. Patentee after: Xi'an Haotian Bioengineering Tech. Co., Ltd. Address before: 110015 Liaoning Province in Dongling District of Shenyang City fengle Street No. 88 Patentee before: Wanjia Biotechnology Inst., Shengyang City Patentee before: Xi'an Haotian Bioengineering Tech. Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160920 Address after: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Patentee after: Liaoning Wanjia Medical Technology Co., Ltd. Patentee after: Xi'an Haotian Bioengineering Tech. Co., Ltd. Address before: Fengle Shenhe District of Shenyang city in Liaoning province 110015 Street No. 88 Patentee before: Shenyang Wanjia Biotechnology Institute Co., Ltd. Patentee before: Xi'an Haotian Bioengineering Tech. Co., Ltd. |